Bortezomib for previously untreated multiple myeloma.
1Catholic University of Leuven, Faculty of Medicine, Hematology Section, Leuven, Belgium. michel.delforge@uzleuven.be
Expert Opinion on Pharmacotherapy
|September 28, 2011
Summary
Bortezomib is a key treatment for multiple myeloma. This review covers its frontline use, efficacy in various patient groups, and managing side effects, highlighting ongoing research for optimal regimens.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- The treatment landscape for multiple myeloma has significantly evolved with novel agents.
- Bortezomib (Velcade), a proteasome inhibitor, and immunomodulatory drugs have revolutionized antimyeloma therapy.
Purpose of the Study:
- To review current data on the frontline application of bortezomib and its combinations in multiple myeloma.
- To consolidate information on bortezomib's efficacy, safety, and optimal use in diverse patient populations.
Main Methods:
- Comprehensive review of preclinical data, pharmacokinetics, and pharmacodynamics of bortezomib.
- Analysis of published clinical trials focusing on first-line bortezomib treatment for transplant-eligible and elderly patients.
- Discussion of bortezomib's utility in specific subgroups, including those with high-risk cytogenetics and renal insufficiency.
Main Results:
- Bortezomib demonstrates significant efficacy as a frontline treatment in multiple myeloma.
- Data supports the use of bortezomib in transplant-eligible, elderly, and high-risk patient groups.
- Management strategies for bortezomib-induced side effects are crucial for patient care.
Conclusions:
- Bortezomib is a foundational element in frontline multiple myeloma treatment regimens.
- Further research is needed to optimize dosing schedules and identify novel combination therapies involving bortezomib.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...